[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Bristol-Myers Squibb Co (BMY)

Bristol Myers Squibb's Opdivo receives FDA Priority Review for Classical Hodgkin Lymphoma, while the company also announced a quarterly dividend increase.

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Co. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines.
Bristol-Myers Squibb Co uses the ticker $BMY for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Bristol-Myers Squibb Co (BMY) market dominance near a 52-week low at XXXXXXX.
Bristol-Myers Squibb Co (BMY) social dominance is up XXXXXX% from the previous month.
Bristol-Myers Squibb Co (BMY) engagements is up XXXXX% from the previous week.
Bristol-Myers Squibb Co (BMY) posts created is up XXXXX% from the previous week.

Price: $XXXXX

Price 24-Hour Time-Series Raw Data
The stock is trading near its 52-week low due to patent cliff concerns, layoffs, and a failed drug trial. However, recent positive clinical trial news and strong social media sentiment suggest a potential rebound.

24-Hour: -XXXX% 7-Day: -XXXX% 30-Day: XXXX%

1-Year High: $XXXXX on 2025-03-10
1-Year Low: $XXXXX on 2025-10-29

AltRank: XXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Bristol-Myers Squibb Co (BMY) is currently AltRank #443 based on combined combined social and market metrics Daily Average: XXX
X Week: XXX -XX
X Month: XXX +25
X Months: XXX +21
X Year: XXX -XXX
1-Year High: XXXXX on 2025-08-24
1-Year Low: XX on 2025-08-01

Galaxy Score: XXXXX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -X
X Month: XX -XX
X Months: XX +22
X Year: XX +20
1-Year High: XX on 2025-07-16
1-Year Low: XX on 2024-12-13

Engagements: XXXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXX
Daily Average: XXXXXX
X Week: XXXXXXX +44%
X Month: XXXXXXXXX -XX%
X Months: XXXXXXXXXX +16%
X Year: XXXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-02-06
1-Year Low: XXXXXX on 2025-05-03

Engagements by network (24h): News: XXX Reddit: XX TikTok: XXX X: XXXXXX YouTube: XXXXX

Mentions: XXX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXXXX -XXXX%
X Months: XXXXXX +32%
X Year: XXXXXX -XX%
1-Year High: XXXXX on 2025-06-27
1-Year Low: XXX on 2025-12-07

Mentions by network (24h): News: XX Reddit: XX TikTok: XX X: XXXXX YouTube: XXX

Creators: XXX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XXX unique social accounts have posts mentioning Bristol-Myers Squibb Co (BMY) in the last XX hours which is down XX% from XXX in the previous XX hours Daily Average: XXX
X Week: XXX -XX%
X Month: XXXXX +6.70%
X Months: XXXXXX +143%
X Year: XXXXXX +106%
1-Year High: XXXXX on 2025-06-27
1-Year Low: XX on 2025-12-07

The most influential creators that mention Bristol-Myers Squibb Co in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@bristolmyerssquibb	X	XXXXX	XX	XXXXX
@BiopharmIQ	X	XXXXXX	X	XXXXX
@yaireinhorn	X	XXXXXX	X	XXXXX
@pauldejong_	X	XXXXX	X	XXX
@TohJah7809	X	XXXXX	X	XXX
@andrewcaravello	X	XXXXX	X	XXX
@nytimes	X	XXXXXXXXXXX	X	XXX
@WallStSai	X	XXXXX	X	XXX
@JacobPlieth	X	XXXXXX	X	XXX
@MarketRebels	XX	XXXXXXX	X	XXX

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% +4%
X Month: XX% +7%
X Months: XX% +15%
X Year: XX% +21%
1-Year High: XX% on 2025-06-27
1-Year Low: XX% on 2025-04-29

Most Supportive Themes:

Pipeline and Clinical Trial Updates: (40%) Bristol-Myers Squibb is presenting positive results from clinical trials for various treatments.
Partnerships and Collaborations: (30%) Bristol-Myers Squibb is forming strategic alliances and collaborations to advance its drug development pipeline.
Financial Performance and Earnings: (20%) Analysts are anticipating significant updates on Bristol-Myers Squibb's financials and pipeline progress.

Most Critical Themes:

Patent Cliffs and Revenue Concerns: (40%) Bristol-Myers Squibb faces significant revenue challenges due to upcoming patent expirations for key drugs.
Stock Performance and Valuation: (35%) The stock has experienced a significant decline, trading near its 52-week low.
Layoffs and Restructuring: (25%) The company has announced significant layoffs as part of a broader cost-cutting strategy.

Social Dominance: XXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.0088%
X Month: XXXX% +0.116%
X Months: XXXX% +0.093%
X Year: XXXX% +0.027%
1-Year High: XXXX% on 2025-06-27
1-Year Low: XXXXX% on 2025-12-07

Market Dominance: XXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXX%
Daily Average: X%
1-Year High: XXXX% on 2025-03-11
1-Year Low: XXXX% on 2025-12-11

Market Cap: $XXXXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXXXX -$1.60%
X Month: $XXXXXXXXXXXXXXX +$5.10%
X Months: $XXXXXXXXXXXXXXX +$3%
X Year: $XXXXXXXXXXXXXXX -$9.60%
1-Year High: $XXXXXXXXXXXXXXX on 2025-03-10
1-Year Low: $XXXXXXXXXXXXXX on 2025-10-29

Top Bristol-Myers Squibb Co News

Top news links shared on social in the last XX hours

Showing a maximum of X news posts for non-authenticated requests. Use your API key in requests for full results.

"Clot-Fighting Drug Plavix Set to Lose Patent Protection - The New York Times"
News Link @nytimes 2025-09-29T20:09Z 228.6M followers, 68.7K engagements

"Baby Formula Sales in Third World Criticized (Published 1975)"
News Link @nytimes 2019-05-08T21:00Z 228.6M followers, 589K engagements